Related Sessions

• Aneuploidy in embryos: variability between centers, between patients and between cycles of the same patients
• Basic principles for the non-geneticist
• Can CMA replace standard karyotyping?
• Carrier screening of recessive disease: Universal screening
• Characterization of the molecular etiology of severe cases of infertility - a must to bring personalized medicine to the field of reproduction
• Chromosomal microarrays - How does it work?
• Clinically evaluating NGS and its extra information
• COGEN Position Statement on Chromosomal Mosaicism Detected in Preimplantation Blastocyst Biopsies
• COGEN Statement on the use of Preimplantation Genetic Screening (PGS) of chromosomes for IVF patients
• Comprehensive Chromosome Screening in IVF: Enhancing Outcomes while reducing the Burden of Care
• Counseling for Variants of Unclear Clinical Significance
• Cumulus cell genomics and its predictive value
• Debate : How should NIPT be used
• Debate: Is it now unethical not to screen out an aneuploidy embryo in IVF?
• Detection of Copy number variants (CNVs) in prenatal diagnosis
• Development and current best practice for translocations
• Gene therapy in reproductive medicine
• History of PGD and PGS
• Introduction of NIPT in clinical practice
• Merging a comprehensive preconception carrier screening panel and chromosomal microarray analysis
• Next generation sequencing: Strategies for genetic testing
• NIPD for Single-Gene Disorders
• NIPT for microdeletion syndromes
• NIPT for partial monosomy for chromosome 13
• NIPT for rare trisomies
• NIPT/MPSS: Expanding the boundaries of prenatal screening
• Online Educational Program
• PGD/PGS
• Pre-conception Screening
• Prenatal
• Procedure related risk of CVS vs. amniocentesis
• Reproductive Genetics
• Serum Screening after NIPT
• Single gene diagnosis and aneuploidy detection using karyomapping
• Social and legal aspects
• Technical aspects of reproductive genetics (Methods of PGS, PGD, Prenatal)
• The placenta as a source for NIPT Discordance
• Update on polar body testing for detection of female meiotic errors
• Will the Fetal Exome Contribute to the Counseling and Management of the Dysmorphic or Malformed Fetus?